title: Granulomatous adenohypophysitis after interferon and ribavirin therapy.
abstract: OBJECTIVE
  To describe a case of granulomatous hypophysitis occurring after treatment with interferon alfa-2b and ribavirin for hepatitis C.
  
  
  METHODS
  Clinical, radiologic, laboratory, and pathologic assessments of a woman with granulomatous hypophysitis and interferon-induced thyroiditis are presented.
  
  
  RESULTS
  A 42-year-old woman with hepatitis C was treated with interferon alfa-2b and ribavirin for 5 months. She was referred after symptoms of thyrotoxicosis developed, in conjunction with laboratory and radiographic evidence of thyroiditis. During the initial evaluation, she was weak and hypotensive; biochemical evaluation showed undetectable plasma cortisol and corticotropin concentrations. Magnetic resonance imaging revealed diffuse enlargement of the pituitary gland, which encroached on but did not compress the optic chiasm. Treatment with supraphysiologic doses of prednisone resulted in clinical and radiographic improvement. Once physiologic doses of glucocorticoids were instituted, however, follow-up magnetic resonance imaging showed substantial progression of the diffuse pituitary enlargement and mild compression of the optic chiasm. Surgical debulking of the mass and histologic evaluation showed chronic, noncaseating granulomatous hypophysitis. An extensive evaluation for secondary causes of granulomatous inflammation of the pituitary revealed only an elevated angiotensin-converting enzyme level; no organisms were identified. After 2 courses of high-dose glucocorticoids, she had radiographic evidence of decreased size of the pituitary lesion but continued to have multiple anterior pituitary hormone deficiencies.
  
  
  CONCLUSIONS
  Granulomatous hypophysitis and sarcoidosis of the pituitary are rare disorders. Hypophysitis should be considered in patients receiving interferon and ribavirin therapy who have symptoms consistent with pituitary dysfunction.
authors.affiliation: Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Tebben
authors.forename: John L D
authors.initials: JL
authors.lastname: Atkinson
authors.forename: Bernd W
authors.initials: BW
authors.lastname: Scheithauer
authors.forename: Dana
authors.initials: D
authors.lastname: Erickson
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006099:Granuloma / Q000139:chemically induced / Q000473:pathology*; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D007018:Hypopituitarism / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D010900:Pituitary Diseases / Q000139:chemically induced / Q000473:pathology*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use; D013966:Thyroiditis / Q000139:chemically induced / Q000473:pathology; D013971:Thyrotoxicosis / Q000139:chemically induced / Q000473:pathology
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin